07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Medicines Co., Chiesi deal

Chiesi will purchase Medicines Co.’s non-core cardiovascular assets, including Cleviprex clevidipine, Kengreal cangrelor and the company’s rights to ready to use argatroban . Medicines Co. will receive $260 million cash up front when the deal...
01:25 , May 10, 2016 |  BC Extra  |  Company News

Medicines Co. selling some CV assets to Chiesi

The Medicines Co. (NASDAQ:MDCO) is selling its non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. (Parma, Italy). The deal includes Cleviprex clevidipine , Kengreal cangrelor and the company's rights to ready to use argatroban . It...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Company News

Medicines Co., SciClone deal

The Medicines Co. granted SciClone exclusive rights to promote cardiovascular drugs Cleviprex clevidipine and Angiomax bivalirudin in China. SciClone will be responsible for all pre- and post-launch commercialization, excluding Hong Kong and Macau. In addition...
02:22 , Dec 19, 2014 |  BC Extra  |  Company News

SciClone will channel Medicines Co. drugs in China

The Medicines Co. (NASDAQ:MDCO) granted SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) exclusive rights to promote cardiovascular drugs Cleviprex clevidipine and Angiomax bivalirudin in China. SciClone, which sells to a network of Chinese hospital cardiac cathlabs, will be...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

Cleviprex clevidipine: Phase III data

Top-line data from the open-label, international Phase III PRONTO trial in 104 emergency department hypertensive AHF patients who exhibited pulmonary congestion showed that IV clevidipine met the composite primary endpoint of median time and percent...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Medicines Co. sales and marketing update

The Medicines Co. launched a 12-hour IV formulation of Cleviprex clevidipine in the U.S. to reduce blood pressure when oral therapy is not feasible or desirable. The wholesale acquisition cost is $85 and $170 for...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Company News

Medicines Co. sales and marketing update

The Medicines Co. recalled an additional four lots of Cleviprex clevidipine due to the potential presence of visible particulate matter, which was observed in some vials during inspection. Medicines Co. licensed exclusive rights to the...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Company News

Medicines Co. cardiovascular news

The Medicines Co. disclosed in an SEC filing that it will reduce its U.S. sales headcount by 43 (26%). The company said it expects annual costs savings of $8-$9 million starting this quarter from the...
23:35 , Feb 12, 2010 |  BC Extra  |  Company News

Medicines Co. cuts U.S. sales force

The Medicines Co. (NASDAQ:MDCO) disclosed in an SEC filing on Friday that it will reduce its U.S. sales force by 43 (26%). The company expects annual costs savings of $8-$9 million from the reduction, which...
08:00 , Feb 8, 2010 |  BioCentury  |  Strategy

Medicines Co. chronicles

Medicines Co. chronicles The Medicines Co. (NASDAQ:MDCO) reached a high of $36.19 per share, or about $1.8 billion in market cap in December 2006. That was up 126% since the company's IPO in mid-2000 at...